I would have posted this on a previous thread, but it seems to be closed. This is a new press release.
"Results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place...